Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous myoblast grafts for ptosis in oculopharyngeal muscular dystrophy
2015-001192-48Phase 2Terminated
- Sponsor
- CHU Caen Normandie
- Start
- Sep 2015
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of autologous skeletal myoblasts in oculopharyngeal muscular dystrophy (OPMD), sponsored by CHU Caen Normandie. Primary endpoint: Improvement in ptosis measured by palpebral fissure opening at 12 months. Started Sep 2015; status: terminated.
02
Drugs
autologous skeletal myoblasts
03
Conditions
oculopharyngeal muscular dystrophy (OPMD)
Beyond the preview
Go deeper on 2015-001192-48.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-001192-48.